Taysha Gene Therapies Stock Price To Earnings To Growth
| TSHA Stock | USD 2.71 0.08 3.04% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Taysha Gene's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Taysha Gene Therapies Company Price To Earnings To Growth Analysis
Taysha Gene's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Taysha Gene Therapies has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Taysha Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taysha Gene's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taysha Gene could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics of similar companies.Taysha Gene is currently under evaluation in price to earnings to growth category among its peers.
Taysha Fundamentals
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (9.31) % | ||||
| Current Valuation | 631.28 M | ||||
| Shares Outstanding | 261.53 M | ||||
| Shares Owned By Insiders | 12.11 % | ||||
| Shares Owned By Institutions | 67.40 % | ||||
| Number Of Shares Shorted | 43.96 M | ||||
| Price To Book | 12.47 X | ||||
| Price To Sales | 95.40 X | ||||
| Revenue | 8.33 M | ||||
| Gross Profit | 7.22 M | ||||
| EBITDA | (87.95 M) | ||||
| Net Income | (89.3 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 63.18 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.27 X | ||||
| Cash Flow From Operations | (81.22 M) | ||||
| Short Ratio | 15.25 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 8.32 | ||||
| Number Of Employees | 73 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 689.14 M | ||||
| Total Asset | 160.36 M | ||||
| Retained Earnings | (602.3 M) | ||||
| Working Capital | 115.9 M | ||||
| Net Asset | 160.36 M |
About Taysha Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taysha Gene Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:Check out Taysha Gene Piotroski F Score and Taysha Gene Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.